Viking Therapeutics (VKTX) – Two Big Catalysts — VKTX Inks Manufacturing Deal, Roche Pays $1.4 Billion ($5.3 Billion with Milestones) for 50% of Zealand Phase II Amylin Obesity Drug

BIOINVEST BREAKING NEWS – Viking (VKTX) – Yesterday VKTX has checked off another important box in its obesity drug competitiveness by securing production capacity for their second generation GLP drug, VK2735. The Company will prepay leading global contract manufacturer CordenPharma (…more)

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.